AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02094482 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.
Description: The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
Study NCT03866577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: M254
Description: M254 administered as intravenous infusion
Study NCT03866577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as intravenous infusion
Study NCT03866577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Description: IVIg administered as intravenous infusion
Study NCT04261803 — intervention group
Intervention type: BIOLOGICAL
Intervention: salivary sample
Description: spit of saliva in a tube
Study NCT04261803 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood test
Description: 2millilitter blood test
Study NCT00750945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and treadmill walking program
Description: Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
Study NCT00750945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking program
Description: Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
Study NCT00750945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home program
Description: Home walking program 6 days/wk x 4 weeks
Study NCT00022516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/day orally continuously for 1 year
Study NCT00022516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year
Study NCT03237689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Low dose hydrocortisone (10mg)
Study NCT03237689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: capsules of starch 1500 powder
Study NCT06649591 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: The intervention is an email based survey as described in the study description.
Study NCT02094989 — intervention group
Intervention type: OTHER
Intervention: posture dependence of VCG-ECG-transformation
Study NCT03969810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rounding Summary
Description: Written summary of rounds
Study NCT03640910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OT Equators® (Rhein83)
Description: Attachment systems to retain an implant overdenture
Study NCT03640910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator® (Zest)
Description: Attachment systems to retain an implant overdenture
Study NCT01083030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: Angioplasty of superficial femoral artery (SFA)
Study NCT01083030 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DCB
Description: Drug Coated Balloon Angioplasty
Study NCT04266977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: restrictive use of DEX, based on standardized clinical and radiological criteria.
Study NCT03378999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhodospirillum rubrum
Description: Capsules containing oven-dried Rhodospirillum rubrum
Study NCT03378999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Capsules containing microcrystalline cellulose
Study NCT00444873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
Description: Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
Study NCT00567996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg once daily (o.d) inhaled
Study NCT00567996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 μg
Description: Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
Study NCT00567996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo to Indacaterol inhaled via SDDPI.
Study NCT00567996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo to Indacaterol inhaled via SDDPI.
Study NCT00567996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo to salmeterol delivered via a proprietary dry powder inhaler
Study NCT00567996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Salmeterol
Description: Placebo to salmeterol delivered via a proprietary dry powder inhaler
Study NCT03478345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endocrine disruptor chemical reduction intervention
Description: Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
Study NCT03271541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
Study NCT01679418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a wound drain post surgery (Redon; Medicoplast)
Description: The wound drain, type Redon Drainage 3.0 mm in diameter
Study NCT01679418 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No-drain after surgery
Description: After surgery, no drain was put
Study NCT03717974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedecine follow-up after an intervention at home of the mobile team
Description: After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized.
Study NCT03717974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile team follow-up after an intervention at home of the mobile team
Description: After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized.
Study NCT01851343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Marrow Stromal Cell (BMSC) Infusion
Description: Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
Study NCT02056301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
Study NCT02056301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
Study NCT00727857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and metformin
Description: Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
Study NCT00727857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
Study NCT00727857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
Study NCT02041429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT02041429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02635438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unique Pharmaceutical Laboratories, India
Description: Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
Study NCT02635438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxane Laboratories Inc., USA
Description: Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
Study NCT03734224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesix mesh
Description: Adhesix mesh
Study NCT03734224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progrip mesh
Description: Progrip mesh
Study NCT00845910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of every 3 week cycle
Study NCT00845910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 900mg/m2 po on days 1-14 of every 3 week cycle
Study NCT00845910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60mg/m2 iv on day 1 of every 3 week cycle
Study NCT05122845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood test (10 tubes of 5mL) :~- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA
Study NCT00964691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: 3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
Study NCT00964691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: 300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
Study NCT02325882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine mixed fentanyl based intravenous PCA
Study NCT02325882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 1
Description: conventional fentanyl-based epidural PCA
Study NCT02325882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 2
Description: conventional fentanyl based intravenous PCA
Study NCT03762226 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF
Description: Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
Study NCT01849367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith Neuroconn tDCS device
Study NCT01849367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eldith Neuroconn tDCS device
Study NCT02051582 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeons using fluoroscopy with laser pointer
Description: Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves.
Study NCT02051582 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeons using fluoroscopy without laser pointer
Description: Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves.
Study NCT02768818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic VIVOMIXX™
Description: The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
Study NCT02768818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
Study NCT03273101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical assisted sit-to-stand training group
Description: Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
Study NCT03273101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual assisted sit-to-stand training group
Description: Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
Study NCT01626001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4D CT scans
Description: 4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
Study NCT02119013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octeotride
Study NCT02119013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05343780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heptex
Description: Dukung Anak 200 mg + Milk thistle 100 mg
Study NCT03394794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor rehabilitation
Description: The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
Study NCT05343780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice bran
Description: Placebo
Study NCT00718614 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
Description: Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
Study NCT03207269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
Study NCT03207269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
Study NCT02448485 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic Valve Intervention (surgical or transcatheter)
Description: Surgical or interventional aortic valve implantation
Study NCT04145154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of platelet rich plasma in chronic wounds of diabetic origin
Description: Application of plasma rich in autologous growht factors after advanced healing
Study NCT02607293 — intervention group
Intervention type: DRUG
Intervention: Long GnRH agonist
Description: As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
Study NCT02607293 — intervention group
Intervention type: DRUG
Intervention: GnRH antagonist
Description: As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
Study NCT03032692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWORD
Description: Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
Study NCT03032692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWORD
Description: Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
Study NCT03032692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with biofeedback
Study NCT03032692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise without biofeedback
Study NCT03013647 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methyl Aminolevulinate
Description: Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face
Study NCT01615445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
Study NCT01615445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
Study NCT03394794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Description: The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
Study NCT01444469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zithromax
Description: 250mg \* 2 capsules once daily for three days
Study NCT01444469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder
Study NCT03540342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One stop strategy group
Description: Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
Study NCT02153697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-switched SINON Ruby Laser
Description: Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
Study NCT02153697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pigmanorm Cream
Description: Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
Study NCT04198610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
Study NCT01071720 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CKD-501 1mg
Description: This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
Study NCT00730925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: tablet BIBW high dose
Study NCT00730925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992 + paclitaxel
Description: tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
Study NCT01954017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STP206
Description: Live Biotherapeutic
Study NCT01954017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sterile Water
Study NCT04315311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CREON
Description: Capsule: Oral
Study NCT03453333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscope
Description: For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.